jsmsJournal of Siberian Medical SciencesJournal of Siberian Medical Sciences2542-1174Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)jsms-740Research ArticleОБЗОРЫREVIEWРак эндометрия (краткий обзор)Uterine cancer at a glanceМимунН.MimouneN.

Мимун Нура — Ph.D., H.D.R., доцент, старший преподаватель; научный сотрудник лаборатории биотехнологий репродукции животных

РВ 270, г. Блида, Алжир

Mimoune Nora — Ph.D., H.D.R., Senior Lecturer, Associate Professor; Permanent Researcher

РВ 270, Blida, Algeria

nora.mimoune@gmail.comАззузМ. Я.AzzouzM. Yu.

Аззуз Мохаммед Яассин — д-р ветеринарии, магистр, факультет естественных наук

Алжир

Azzouz Mohamed Yassine — D.V.M., M.S.

Algeria

БенаджельУ.BenadjelO.

Бенаджель Умайма — д-р ветеринарии, магистр

Алжир

Benadjel Oumayma — D.V.M., M.S.

Algeria

КелефД.KhelefD.

Келеф Джамель — Ph.D., H.D.R., профессор

Алжир

Khelef Djamel — Ph.D., H.D.R., Full Professor

Algeria

КаидиР.KaidiR.

Каиди Рашид — Ph.D., H.D.R., профессор

Алжир

Kaidi Rachid — Ph.D., H.D.R., Full Professor

Algeria

Национальная высшая школа ветеринарии; Институт ветеринарии, лаборатория биотехнологий репродукции животных, Университет Блиды 1АлжирNational High School of Veterinary; Institute of Veterinary Sciences, Laboratory of Biotechnologies Related to Animal Reproduction, University of Blida 1AlgeriaУниверситет Блиды 1, факультет естественных наукАлжирUniversity of Blida 1, Faculty of Nature and Life SciencesAlgeriaНациональная высшая школа ветеринарии (г. Алжир, Баб-Эззуар, Алжир)АлжирNational High School of VeterinaryAlgeriaИнститут ветеринарии, лаборатория биотехнологий репродукции животных, Университет Блиды 1 (Алжир)АлжирInstitute of Veterinary Sciences, Laboratory of Biotechnologies Related to Animal Reproduction, University of Blida 1Algeria20212509202103116136Copyright © Мимун Н., Аззуз М.Я., Бенаджель У., Келеф Д., Каиди Р., 20212021Мимун Н., Аззуз М.Я., Бенаджель У., Келеф Д., Каиди Р.Mimoune N., Azzouz M.Y., Benadjel O., Khelef D., Kaidi R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://jsms.elpub.ru/jour/article/view/740

Злокачественные новообразования тела матки (ЗНТМ) занимают 6-е место в структуре гинекологического рака (среди новых случаев рака у женщин в 2012 г.) и 15-е — среди всех видов рака. В 2018 г. в мире зарегистрировано 382 069 новых случаев ЗНТМ и 89 929 вызванных этим заболеванием смертей. Таким образом, в 2018 г. ЗНТМ были 2-м наиболее распространенным типом гинекологического рака и занимали 4-е место в структуре женской смертности вследствие гинекологического рака. Ожидается, что к 2040 г. смертность вследствие ЗОЭ ЗНТМ вырастет более чем вдвое. Наиболее низкий уровень смертности вследствие ЗНТМ отмечается в Центральной и Южной Азии, максимальный — в Африке. У выживших после злокачественных опухолей матки могут воз- никнуть проблемы, связанные с проведенным лечением — бесплодие, раннее наступление менопаузы, расстройства сексуальной сферы и лимфедема нижних конечностей. Всемирная организация здравоохранения создает собственную базу данных на основе национальных оценок заболеваемости, используя метод выборки, который опирается на вычисления средневзвешенного или простого среднего наиболее распространенных коэффициентов- показателей для населения ряда регионов, либо на приблизительную оценку, основанную на данных, предоставленных медицинскими учреждениями стран-соседей. В Алжире существующая система статистического и эпидемиологического учета не так совершенна. В связи с этим целью нашего обзора являлось освещение современной ситуации по ЗНТМ в Алжире и краткое представление основных аспектов (этиология, диагностика и лечение) этой патологии.

Among gynecological tumors, malignant uterine tumor (MUT) is the 6th most common cancer in women and the 15th most common cancer overall. There were approximately 382 069 new cases and 89 929 deaths attributed to this type worldwide in 2018. Therefore, MUT was the second most common gynecological cancer and the fourth leading cause of death due to gynecological cancer in 2018, and is expected to increase the incidence rate by more than 50% globally by 2040. Mortality rates are lowest in Central and South Asia and most of Africa. Survivors of MUT may experience treatment- related issues, including infertility, early onset of menopause, sexual problems, and lower limb lymphedema. WHO builds its own database from national modeling incidence estimates, using incidence ratios with a sampling method that relies on the calculation of a weighted or simple average of the most popular local rates applied to the population of a few regions or by an approximate estimate based on data provided by health establishments in neighboring countries. While in Algeria, existing statistical and epidemiological data and updated information on the pathology are insuffi cient. The objective of this work is to highlight the importance and the situation of the MUT in this country and to describe the different recent aspects (etiology, diagnostics and treatment) related to the disease.

матказлокачественная опухольженщинастатистикаэтиологиядиагностикалечениеАлжирuterusmalignant tumorwomanstatisticsetiologydiagnosticstreatmentAlgeriaReferencesTaylan E., Oktay K. Fertility preservation in gynecologic cancers // Gynecol. Oncol. 2019. Vol. 155 (3). P. 522–529. doi: 10.1016/j.ygyno.2019.09.012.Taylan E., Oktay K. (2019). Fertility preservation in gynecologic cancers. Gynecol. Oncol., 155 (3), 522–529. doi: 10.1016/j.ygyno.2019.09.012.Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer. J. Clin. 2018. Vol. 68 (6). P. 394–424.Bray F., Ferlay J., Soerjomataram I. et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer. J. Clin., 68 (6), 394–424.Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. A Summary of the Third Expert Report. Continous Update Project. 2018. 112 p.Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. A Summary of the Third Expert Report. Continous Update Project. 2018. 112 p.Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2015. Vol. 136 (5). P. E359–E386.Ferlay J., Soerjomataram I., Dikshit R. et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer., 136 (5), E359–E386.Torre L.A., Farhad I., Siegel R.L., Ward E.M., Ahmedin J. Global cancer in women: burden and trends // Cancer Epidemiol. Biomarkers Prev. 2017. Vol. 26 (4). P. 444–457.Torre L.A., Farhad I., Siegel R.L., Ward E.M., Ahmedin J. (2017). Global cancer in women: burden and trends. Cancer Epidemiol. Biomarkers Prev., 26 (4), 444–457.Zhang S., Gong T.T., Liu F.H. et al. Global, Regional, and National Burden of Endometrial Cancer, 1990– 2017: Results From the Global Burden of Disease Study, 2017 // Front. Oncol. 2019. Vol. 9: 1440. doi: 10.3389/fonc.2019.01440.Zhang S., Gong T.T., Liu F.H. et al. (2019). Global, Regional, and National Burden of Endometrial Cancer, 1990–2017: Results from the Global Burden of Disease Study, 2017. Front. Oncol., 9, 1440. doi: 10.3389/fonc.2019.01440.Hamdi Cherif M., Bidoli E., Birri S. et al. Cancer estimation of incidence and survival in Algeria 2014 // J. Cancer. Res. Ther. 2015. Vol. 3 (9). P. 100–104.Hamdi Cherif M., Bidoli E., Birri S. et al. (2015). Cancer estimation of incidence and survival in Algeria 2014. J. Cancer. Res. Ther., 3 (9), 100–104.World Cancer Report: Cancer Research for Cancer Prevention / ed. by C.P. Wild, E. Weiderpass, B.W. Stewart. Lyon, France, 2020. URL: http://publications.iarc.fr/586. Дата обращения: 10.06.2021.Wild C.P., Weiderpass E., Stewart B.W. (eds.). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France, 2020. Retrieved June 10, 2021 from http://publications.iarc.fr/586.Global Cancer Observatory. 2018. URL: https://gco.iarc.fr. Дата обращения: 10.06.2021.Global Cancer Observatory. 2018. Retrieved June 10, 2021 from https://gco.iarc.fr.Institut National de Santé Publique. 2019. URL: http://www.insp.dz/index.php/publications/registres-destumeurs-d-alger.html. Дата обращения: 10.06.2021.Institut National de Santé Publique. 2019. Retrieved June 10, 2021 from http://www.insp.dz/index.php/publications/registres-des-tumeurs-d-alger.html.Gospodarowicz M., Benedet L., Hutter R.V. et al. History and international developments in cancer staging // Cancer Prev. Control. 1998. Vol. 2 (6). P. 262–268.Gospodarowicz M., Benedet L., Hutter R.V. et al. (1998). History and international developments in cancer staging. Cancer Prev. Control., 2 (6), 262–268.Benedet J.L. History of the Annual Report // Int. J. Gynecol. Obstet. 2006. Vol. 95 (1). P. S1–S2.Benedet J.L. (2006). History of the Annual Report. Int. J. Gynecol. Obstet., 95 (1), S1–S2.Denoix P.F., Schwartz D. General rules for classifi cation of cancers and presentation of the therapeutic results // Mem. Acad. Chir. 1959. Vol. 85. P. 415–424. In French.Denoix P.F., Schwartz D. (1959). General rules for classifi cation of cancers and presentation of the therapeutic results. Mem. Acad. Chir., 85, 415–424. In French.Kottmeier H.L. Annual Report on the Results of Treatment in Gynecological Cancer. FIGO, 1982.Kottmeier H.L. Annual Report on the Results of Treatment in Gynecological Cancer. FIGO, 1982.Wittekind C., Greene F.L., Hutter R.V.P., Klimpfi nger M., Sobin L.H. TNM Atlas. Guide Illustré de la Classifi cation TNM/pTNM des Tumeurs Malignes. 5th ed. Springer, 2005. In French.Wittekind C., Greene F.L., Hutter R.V.P., Klimpfi nger M., Sobin L.H. TNM Atlas. Guide Illustré de la Classifi cation TNM/pTNM des Tumeurs Malignes. 5th ed. Springer, 2005. In French.Carcopino X., Levêque J., Riethmuller D. Cancers Gynécologiques Pelviens. Elsevier Masson, 2013. 460 p.Carcopino X., Levêque J., Riethmuller D. Cancers Gynécologiques Pelviens. Elsevier Masson, 2013. 460 p.Suarez A.A., Felix A.S., Cohn D.E. Bokhman Redux: Endometrial cancer “types” in the 21st century // Gynecol. Oncol. 2017. Vol. 144 (2). P. 243–249. doi: 10.1016/j.ygyno.2016.12.010.Suarez A.A., Felix A.S., Cohn D.E. (2017). Bokhman redux: Endometrial cancer “types” in the 21st century. Gynecol. Oncol., 144 (2), 243–249. doi: 10.1016/j.ygyno.2016.12.010.Wilczyński M., Danielska J., Wilczyński J. An update of the classical Bokhman’s dualistic model of endometrial cancer // Menopause. Rev. 2016. Vol. 15 (2). P. 63–68. doi: 10.5114/pm.2016.61186.Wilczyński M., Danielska J., Wilczyński J. (2016). An update of the classical Bokhman’s dualistic model of endometrial cancer. Menopause Rev., 15 (2), 63–68. doi: 10.5114/pm.2016.61186.Just P.A., Borghese B., Alexandre J. Classifi cation des carcinomes de l’endomètre et de l’ovaire // Correspondances en Onco-Théranostic. 2015. Vol. 4 (4). P. 140–149. In French.Just P.A., Borghese B., Alexandre J. (2015). Classifi cation des carcinomes de l’endomètre et de l’ovaire. Cor respondances en Onco-Théranostic, 4 (4), 140–149. In French.Kandoth C., Schultz N., Cherniack A.D. et al. Integrated genomic characterization of endometrial carcinoma // Nature. 2013. Vol. 497 (7447). P. 67–73.Kandoth C., Schultz N., Cherniack A.D. et al. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497 (7447), 67–73.Blair A.R., Casas C.M. Gynecologic сancers // Prim. Care Clin. Offi ce Pract. 2009. Vol. 36 (1). P. 115–130. doi: 10.1016/j.pop.2008.10.001.Blair A.R., Casas C.M. (2009). Gynecologic сancers. Prim. Care Clin. Offi ce Pract., 36 (1), 115–130. doi: 10.1016/j.pop.2008.10.001.El-Harrak M. Education thérapeutique des patients atteints de cancer. Thèse de Doctorat en Pharmacie. Univ. Mohamed V. Faculté de médecine et de pharmacie, Rabat, Maroc, 2016. In French.El-Harrak M. Education thérapeutique des patients atteints de cancer. Thèse de Doctorat en Pharmacie. Univ. Mohamed V. Faculté de médecine et de pharmacie, Rabat, Maroc, 2016. In French.Bats A.S., Rossi L., Le Frere-Belda M.A. et al. Lynch syndrome and endometrial cancer // Bull. Cancer. 2017. Vol. 104 (12). P. 1013–1021.Bats A.S., Rossi L., Le Frere-Belda M.A. et al. (2017). Lynch syndrome and endometrial cancer. Bull. Cancer., 104 (12), 1013–1021.Reid-Nicholson M., Iyengar P., Hummer A.J. et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis // Modern Path. 2006. Vol. 19 (8). P. 1091–1100.Reid-Nicholson M., Iyengar P., Hummer A.J. et al. (2006). Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Modern Path., 19 (8), 1091–1100.American Cancer Society. Global Cancer Facts & Figures. 4th ed. Atlanta: American Cancer Society, 2018.American Cancer Society. Global Cancer Facts & Figures. 4th ed. Atlanta: American Cancer Society, 2018.Jain M.G., Rohan T.E., Howe G.R., Miller A.B. A cohort study of nutritional factors and endometrial cancer // Eur. J. Epidemiol. 2000. Vol. 16. P. 899–905.Jain M.G., Rohan T.E., Howe G.R., Miller A.B. (2000). A cohort study of nutritional factors and endometrial cancer. Eur. J. Epidemiol., 16, 899–905.Collinet P., Poncelet P., Vinatier D. Cancer de l’endomètre // J. Gynécol. Obstétr. Biol. Reprod. 2008. Vol. 37 (2). P. F57–F63.Collinet P., Poncelet P., Vinatier D. (2008). Cancer de l’endomètre. J. Gynécol. Obstétr. Biol. Reprod., 37 (2), F57–F63.Selbey J.V., Friedman G.D., Herrinton L.J. Pharmaceuticals other than hormones // Cancer Epidemiology and Prevention / ed. by D. Schottenfeld, J.F. Fraumeni. New York, Oxford University Press, 1996. P. 489–501.Selbey J.V., Friedman G.D., Herrinton L.J. Pharmaceuticals other than hormones. In D. Schottenfeld, J.F. Fraumeni. Cancer Epidemiology and Prevention (pp. 489–501). New York, Oxford University Press, 1996.Pisani P., Parkin D.M., Muñoz N., Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990 // Cancer Epidemiol. Biomarkers Prev. 1997. Vol. 6 (6). P. 387–400.Pisani P., Parkin D.M., Muñoz N., Ferlay J. (1997). Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev., 6 (6), 387–400.Baillet. Cours : Cancérologie. Chapitre 3. Université Pierre et Marie Curie. Faculté de médecine. Service de radiothérapie. Niveau DCEM3, 2015. In French.Baillet. Cours: Cancérologie. Chapitre 3 (2015). Université Pierre et Marie Curie. Faculté de médecine. Service de radiothérapie. Niveau DCEM3. In French.Belhaddad E.H. La prise en charge du cancer de l’endomètre au CHU Med VI de Marrakech entre 2009 et 2017. Thèse N° 027. Faculté de médecine. Univ. Marrakech, 2019. In French.Belhaddad E.H. (2019). La prise en charge du cancer de l’endomètre au CHU Med VI de Marrakech entre 2009 et 2017. Thèse N° 027. Faculté de médecine. Univ. Marrakech. In French.Goodman A. Endometrial cancer: screening, diagnosis, and surgical staging // F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment. Springer, 2018. P. 13–24.Goodman A. (2018). Endometrial cancer: screening, diagnosis, and surgical staging. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 13–24). Springer.Anatomie-pathologique. Polycopie. Collège Français des Pathologistes. Ch. 1, 7–11. 2012.Anatomie-pathologique. Polycopie (2012). Collège Français des Pathologistes. Ch. 1, 7–11.Pautier P., Haie-Meder C. Les Cancers de l’endomètre. Fondation ARC. Pour la Recherche. Sur le Cancer. 2013. 29 p.Pautier P., Haie-Meder C. (2013). Les Cancers de l’endomètre. Fondation ARC. Pour la Recherche. Sur le Cancer. 29 p.Merritt M.A., Cramer D.W. Molecular pathogenesis of endometrial and ovarian cancer // Cancer. Biomark. 2010. Vol. 9 (1–6). P. 287–305.Merritt M.A., Cramer D.W. (2010). Molecular pathogenesis of endometrial and ovarian cancer. Cancer. Biomark., 9 (1–6), 287–305.Soslow R.A., Oliva E. Uterine cancer: pathology // Uterine Cancer: Screening, Diagnosis, and Treatment / ed. by F. Muggia, E. Oliva. Humana Press, Springer Science + Business Media. New York, 2009.Soslow R.A., Oliva E. (2009). Uterine cancer: pathology. In F. Muggia, E. Oliva (eds.). Uterine Cancer: Screening, Diagnosis, and Treatment. Humana Press, Springer Science + Business Media. New York.Allen D.C. Histopathology Reporting. Guidelines for Surgical Cancer. 2nd ed. Springer, 2006. P. 239–293.Allen D.C. (2006). Histopathology Reporting. Guidelines for Surgical Cancer. 2nd ed. Springer, 239–293.Ellenson L.H. Endometrial carcinoma — molecular genetic aspects // Molecular Pathology of Gynecologic Cancer / ed. by A. Giordana, A. Bovicelli, R.J. Kurman. Humana Press, New Jersey, 2007. P. 99–108.Ellenson L.H. (2007). Endometrial carcinoma — molecular genetic aspects / In A. Giordana, A. Bovicelli, R.J. Kurman (eds.) Molecular Pathology of Gynecologic Cancer (pp. 99–108). Humana Press, New Jersey.Buza N. HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand // Arch. Pathol. Lab. Med. 2021. Vol. 145 (6). P. 687–691. doi: 10.5858/arpa.2020-0207-ra.Buza N. (2021). HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch. Pathol. Lab. Med., 145 (6), 687–691. doi: 10.5858/arpa.2020-0207-ra.Sutton C. Hysterectomy: a historical perspective // Baill. Clin. Obstet. Gynaecol. 1997. Vol. 11 (1). P. 1–22.Sutton C. (1997). Hysterectomy: a historical perspective. Baill. Clin. Obstet. Gynaecol., 11 (1), 1–22.Deffi eux X., de Rochambeau B., Ghêne G. et al. Hysterectomy for benign pathology: Guidelines for clinical practice // J. Gynecol. Obstet. Biol. Reprod. (Paris). 2015. Vol. 44 (10). P. 1219–1227.Deffi eux X., de Rochambeau B., Ghêne G. et al. (2015). Hysterectomy for benign pathology: Guidelines for clinical practice. J. Gynecol. Obstet. Biol. Reprod. (Paris), 44 (10), 1219–1227.Van der Meij E., Emanuel M.H. Hystérectomie pour saignement menstruel abondant. 2016. Vol. 12 (1). P. 63–69.Van der Meij E., Emanuel M.H. (2016). Hystérectomie pour saignement menstruel abondant. 12 (1), 63–69.Agostini A., Bretelle F., Cravello L. et al. Vaginal hysterectomy in nulliparous women without prolapse: a prospective comparative study // BJOG. 2003. Vol. 110 (5). P. 515–518.Agostini A., Bretelle F., Cravello L. et al. (2003). Vaginal hysterectomy in nulliparous women without prolapse: a prospective comparative study. BJOG, 110 (5), 515–518.Balogun O., Lymberis S., Schiff P.B. Early-stage endometrial cancer: radiation — less may be more // F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment. Springer, 2018. P. 183–200.Balogun O., Lymberis S., Schiff P.B. (2018). Early-stage endometrial cancer: radiation — less may be more. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 183–200). Springer.Duska L.R. Primary hormonal therapy of endometrial cancer // F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment. Springer, 2018. P. 151–169.Duska L.R. (2018). Primary hormonal therapy of endometrial cancer. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 151–169). Springer.Musa F. Treatment of advanced and recurrent carcinoma: chemotherapy // F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment. Springer, 2018. P. 223–234.Musa F. (2018). Treatment of advanced and recurrent carcinoma: chemotherapy. In F. Muggia, A.D. Santin, E. Oliva (eds.) Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 223–234). Springer.Shen L., Hong L., Zhou S., Zhang G., Mai R. Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma // Int. J. Clin. Exp. Patho. 2019. Vol. 12 (3). P. 996–1002.Shen L., Hong L., Zhou S., Zhang G., Mai R. (2019). Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma. Int. J. Clin. Exp. Path., 12 (3), 996–1002.Pant A., Lee I.I., Lu Z. et al. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin // PLoS One. 2012. Vol. 7 (7): e41593.Pant A., Lee I.I., Lu Z. et al. (2012). Inhibition of AKT with the orally active allosteric AKT inhibitor, MK- 2206, sensitizes endometrial cancer cells to progestin. PLoS One, 7 (7), e41593.Konecny G.E., Santos L., Winterhoff B. et al. HER2 gene amplifi cation and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer // Br. J. Cancer. 2008. Vol. 100. P. 89–95.Konecny G.E., Santos L., Winterhoff B. et al. (2008). HER2 gene amplifi cation and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br. J. Cancer, 100, 89–95.Luz R., Ferreira J., Rocha M., Félix A. Uterine carcinosarcoma: clinicopathological features and prognostic factors // Acta Médica Portuguesa. 2016. Vol. 29 (10). P. 621. In Portuguese.Luz R., Ferreira J., Rocha M., Félix A. (2016). Uterine carcinosarcoma: clinicopathological features and prognostic factors. Acta Médica Portuguesa, 29 (10), 621. In Portuguese.Black J.D., Roque D.M., Gold L.I., Santin A.D. Future directions and new targets in endometrial cancer // F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment. Springer, 2018. P. 259–271.Black J.D., Roque D.M., Gold L.I., Santin A.D. (2018). Future directions and new targets in endometrial cancer. In F. Muggia, A.D. Santin, E. Oliva. Uterine Cancer: Screening, Diagnosis, and Treatment (pp. 259–271). Springer.Duska L.R., Garrett A., Rueda B.R. et al. Endometrial cancer in women 40 years old or younger // Gynecol. Onc ol. 2001. Vol. 83 (2). P. 388–393.Duska L.R., Garrett A., Rueda B.R. et al. (2001). Endometrial cancer in women 40 years old or younger. Gynecol. Oncol., 83 (2), 388–393.Park J.Y., Seong S.J., Kim T.J. et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer // Obstet. Gynecol. 2013. Vol. 121 (1). P. 136–142.Park J.Y., Seong S.J., Kim T.J. et al. (2013). Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet. Gynecol., 121 (1), 136–142.54.Fleming C.A., Heneghan H.M., O’Brien D. et al. Metaanalysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy // Br. J. Surg. 2018. Vol. 105 (9). P. 1098–1106.Fleming C.A., Heneghan H.M., O’Brien D. et al. (2018). Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg., 105 (9), 1098–1106.

The authors declare that there are no conflicts of interest present.